ABP-2019 (#1162)
Laufzeit: 01.01.2020 - 31.12.2040
imported
Kurzfassung
Advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping
Laufzeit: 01.01.2020 - 31.12.2040
Advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping